Top 5 Articles From the Print Publication in 2023

News
Article

Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.

Articles about upcoming approvals and Humira biosimilars were among those that garnered the most interest.

Here are the five articles published in the print publication of Managed Healthcare Executive that had the most pageviews when they were posted on the MHE website.

4 Important Approvals Expected This Year

The approval of Mounjaro (tirzepatide) for weight loss could be a tipping point for weight-loss drugs. [The weight-loss version of tirzepatide is being sold under the brand-name Zepbound.]

Read more

’Tis the Year of the Humira Biosimilars

As many as 10 Humira biosimilars [it wound up being just 8] may be on the U.S. market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.

Read more

The List of PBM Formulary Exclusions Got Longer in 2023

Pharmacy benefit managers say they exclude high-cost drugs and have alternatives on their formularies. Critics say exclusions narrow patient options and may put effective medication financially out of reach.

Read more

Why States Are Allowing Pharmacies to Dispense Returned Oncology Drugs


Repositories of donated drugs in 13 states are redistributing oncology medications to those in need.

Read more

Antibody-Drug Conjugates Find and Kill Cancer Cells


Three ADCs are in late-stage trials as treatments for patients with non-small cell lung cancer.

Read more

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.